ABBV Stock Recent News
ABBV LATEST HEADLINES
AbbVie is a profitability superstar with a strong track record of success, generating almost 40% in free cash flow margin. The company has a diverse portfolio of products across several promising drug markets, including an intact position in the immunology drugs market. The stock offers an attractive valuation, a solid dividend yield, and is recommended as a "Strong Buy" for long-term investors.
AbbVie's stock has outperformed the market over the past decade, with a 248.90% appreciation. Despite losing patent protection for Humira, which accounted for 37% of revenue in 2022, AbbVie remains undervalued and continues to grow its dividend. AbbVie's recent acquisitions and robust pipeline position the company for future growth and expansion.
The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.
Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
AbbVie's dividend payout has more than tripled over the past decade, and it could soar much further in the decade ahead. Bristol Myers Squibb offers a juicy 4.7% dividend yield at recent prices.
In the latest trading session, AbbVie (ABBV) closed at $169.80, marking a -0.12% move from the previous day.
AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing revenues, compared to 4.6x for JNJ.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.